Study of an oral schizophrenia drug for adults
Part of Mental health clinical trials.
This trial tests an experimental oral drug (emraclidine) to see if it helps symptoms of schizophrenia and how it moves through the body. It looks at two groups of participants: those with stable symptoms and those having an acute flare-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 40 on the body mass index (BMI) scale and weigh more than 110 pounds.
- For the stable group (Part A): your symptoms must be relatively mild (PANSS total score under 80).
- For the acute symptom group (Part B): you must have had a sudden worsening of psychotic symptoms in the last 2 months.
- For Part B: your symptom score must be between 80 and 120 on the PANSS scale, and you must have at least two moderate or worse positive symptoms (like hallucinations or delusions).
- You cannot have a primary diagnosis other than schizophrenia (except for nicotine or caffeine use) in the last year.
- You must not have been treated with clozapine or have had two or more failed medication trials for schizophrenia in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
This trial tests a new medication called SEP-363856 for people with schizophrenia who are currently having a severe flare-up of symptoms. It aims to see if the drug is safe and effective compared to a placebo.
This trial tests a new medication called SEP-363856 over a long period for people with schizophrenia who are currently stable. It looks at how well the drug works and its safety over time.
This trial tests if LY03020 helps people with schizophrenia who are currently having a severe episode. If you have acute symptoms like hallucinations or delusions, this study could be an option.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.